Sumitomo Mitsui DS Asset Management Company Ltd Decreases Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Sumitomo Mitsui DS Asset Management Company Ltd lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 11.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 50,806 shares of the medical research company's stock after selling 6,667 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd's holdings in IQVIA were worth $11,755,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. HighTower Advisors LLC grew its holdings in shares of IQVIA by 2.4% during the first quarter. HighTower Advisors LLC now owns 5,055 shares of the medical research company's stock worth $1,168,000 after purchasing an additional 118 shares in the last quarter. Prudential PLC purchased a new position in shares of IQVIA during the first quarter worth about $741,000. Baird Financial Group Inc. grew its holdings in shares of IQVIA by 2.3% during the first quarter. Baird Financial Group Inc. now owns 99,566 shares of the medical research company's stock worth $23,021,000 after purchasing an additional 2,201 shares in the last quarter. Parkside Financial Bank & Trust grew its holdings in shares of IQVIA by 59.0% during the first quarter. Parkside Financial Bank & Trust now owns 388 shares of the medical research company's stock worth $90,000 after purchasing an additional 144 shares in the last quarter. Finally, Covestor Ltd grew its holdings in shares of IQVIA by 82.2% during the first quarter. Covestor Ltd now owns 554 shares of the medical research company's stock worth $128,000 after purchasing an additional 250 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Insider Buying and Selling

In other IQVIA news, insider Ari Bousbib sold 31,678 shares of the firm's stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the sale, the insider now directly owns 796,752 shares in the company, valued at $199,610,278.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other IQVIA news, insider Eric Sherbet sold 1,000 shares of the firm's stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the sale, the insider now directly owns 20,836 shares in the company, valued at $5,031,894. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ari Bousbib sold 31,678 shares of the firm's stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the completion of the sale, the insider now owns 796,752 shares of the company's stock, valued at $199,610,278.56. The disclosure for this sale can be found here. Insiders have sold 41,285 shares of company stock valued at $10,331,003 over the last ninety days. 1.60% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Evercore ISI boosted their price objective on IQVIA from $255.00 to $265.00 and gave the stock a "market outperform" rating in a report on Thursday, February 15th. Guggenheim lowered IQVIA from a "buy" rating to a "neutral" rating in a research note on Thursday, February 15th. StockNews.com raised shares of IQVIA from a "hold" rating to a "buy" rating in a research note on Friday, February 16th. Barclays upped their price objective on shares of IQVIA from $260.00 to $265.00 and gave the company an "overweight" rating in a research note on Thursday, February 15th. Finally, Leerink Partnrs reiterated an "outperform" rating on shares of IQVIA in a research report on Monday, February 26th. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. Based on data from MarketBeat, IQVIA presently has an average rating of "Moderate Buy" and a consensus price target of $256.80.

IQVIA Trading Up 0.4 %

Shares of NYSE IQV traded up $0.92 during trading hours on Friday, hitting $228.09. The company's stock had a trading volume of 776,957 shares, compared to its average volume of 688,892. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.86 and a current ratio of 0.86. The stock has a market cap of $41.40 billion, a price-to-earnings ratio of 31.29, a P/E/G ratio of 2.21 and a beta of 1.50. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The business has a 50-day simple moving average of $244.82 and a 200-day simple moving average of $222.04.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.82 by $0.02. The company had revenue of $3.87 billion for the quarter, compared to analysts' expectations of $3.80 billion. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. IQVIA's quarterly revenue was up 3.5% on a year-over-year basis. During the same period last year, the firm earned $2.54 earnings per share. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.